The Indian Pharmaceutical Association (IPA) of Telangana State Branch in association with All India Drugs Control Officers Confederation (AIDCOC) along with the support of Pharmexcil is organizing a symposium titled ‘Regulator to Facilitator’ on 10th June 2017 at Radisson Blue Hotel in Hyderabad.
According to Ravi Uday Bhaskar, Director General of Pharmexcil, the main objective of the symposium is to help create a common platform for the senior members from the pharma industry, officials from the Central drugs and standard control Organization (CDSCO) and Drug control Administration of Telangana State who can come together and deliberate on various contemporary issues pertaining to the pharma industry and regulators.
The symposium is expected to deliberate on issues pertaining to regulatory changes that are being incorporated from time to time and at the same time understand the industry point of view with regard to issues concerning licensing and renewing of new products etc. “As part of the symposium an interactive meeting of senior level pharma industry personnel with the officials of CDSCO and state drug control administration (TSDCA) is expected to deliberate on various issues concerning pharma industry and the regulators. This is the best opportunity for the members of pharma Industry to interact with the regulators on issues relating to various regulations governing the industry and at the same time the regulators can understand the industry point of view and both sides can facilitate a common pathway to resolve issues and enhance quality and at the same time also help the industry to enable faster growth,” informed Ravi Uday Bhaskar, Director General of Pharmexcil.
In view of this, the organizers have chosen the theme of "Regulator to Facilitator" for the symposium. “The DGCI apart from performing its role of a regulator is also a facilitator of the Pharma Industry and guides the management of healthcare system in the country. As the overall combined objective is to ensure the Indian Companies produce quality medicines at an affordable price to the patients. We are supporting this symposium to bring forth clarifications, suggestions, and guidance on regulatory insights from the state, central regulators and eminent pharma industry in resolving various issues,” said Uday Bhaskar.